These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 10438707)
1. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Falkenburg JH; Wafelman AR; Joosten P; Smit WM; van Bergen CA; Bongaerts R; Lurvink E; van der Hoorn M; Kluck P; Landegent JE; Kluin-Nelemans HC; Fibbe WE; Willemze R Blood; 1999 Aug; 94(4):1201-8. PubMed ID: 10438707 [TBL] [Abstract][Full Text] [Related]
2. T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation. Smit WM; Rijnbeek M; van Bergen CA; Fibbe WE; Willemze R; Falkenburg JH Proc Natl Acad Sci U S A; 1998 Aug; 95(17):10152-7. PubMed ID: 9707616 [TBL] [Abstract][Full Text] [Related]
3. Minor histocompatibility antigen-specific, leukemia-reactive cytotoxic T cell clones can be generated in vitro without in vivo priming using chronic myeloid leukemia cells as stimulators in the presence of alpha-interferon. Faber LM; van Luxemburg-Heijs SA; Rijnbeek M; Willemze R; Falkenburg JH Biol Blood Marrow Transplant; 1996 Feb; 2(1):31-6. PubMed ID: 9078352 [TBL] [Abstract][Full Text] [Related]
4. The progenitor cell inhibition assay to measure the anti-leukemic reactivity of T cell clones against acute and chronic myeloid leukemia. van der Hoorn MA; van Luxemburg-Heijs SA; van Bergen CA; Bongaerts R; Willemze R; Falkenburg JH Methods; 2003 Oct; 31(2):113-9. PubMed ID: 12957568 [TBL] [Abstract][Full Text] [Related]
5. Molecular persistence of chronic myeloid leukemia caused by donor T cells specific for lineage-restricted maturation antigens not recognizing immature progenitor-cells. von dem Borne PA; van Luxemburg-Heijs SA; Heemskerk MH; Jedema I; Mulder A; Willemze R; Falkenburg JH Leukemia; 2006 Jun; 20(6):1040-6. PubMed ID: 16525495 [TBL] [Abstract][Full Text] [Related]
6. Generation of CD4+ cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity. Faber LM; van Luxemburg-Heijs SA; Veenhof WF; Willemze R; Falkenburg JH Blood; 1995 Oct; 86(7):2821-8. PubMed ID: 7670118 [TBL] [Abstract][Full Text] [Related]
7. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation. Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710 [TBL] [Abstract][Full Text] [Related]
8. Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukemia after allogeneic stem cell transplantation. Marijt E; Wafelman A; van der Hoorn M; van Bergen C; Bongaerts R; van Luxemburg-Heijs S; van den Muijsenberg J; Wolbers JO; van der Werff N; Willemze R; Falkenburg F Haematologica; 2007 Jan; 92(1):72-80. PubMed ID: 17229638 [TBL] [Abstract][Full Text] [Related]
9. Cytotoxic T-lymphocyte (CTL) responses against acute or chronic myeloid leukemia. Falkenburg JH; Smit WM; Willemze R Immunol Rev; 1997 Jun; 157():223-30. PubMed ID: 9255633 [TBL] [Abstract][Full Text] [Related]
10. Generation of leukemia-reactive cytotoxic T lymphocytes from HLA-identical donors of patients with chronic myeloid leukemia using modifications of a limiting dilution assay. Smit WM; Rijnbeek M; van Bergen CA; Willemze R; Falkenburg JH Bone Marrow Transplant; 1998 Mar; 21(6):553-60. PubMed ID: 9543058 [TBL] [Abstract][Full Text] [Related]
11. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease. Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886 [TBL] [Abstract][Full Text] [Related]
12. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells. Zorn E; Wang KS; Hochberg EP; Canning C; Alyea EP; Soiffer RJ; Ritz J Clin Cancer Res; 2002 Jul; 8(7):2052-60. PubMed ID: 12114403 [TBL] [Abstract][Full Text] [Related]
13. Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells. Barbui AM; Borleri G; Conti E; Ciocca A; Salvi A; Micò C; Introna M; Rambaldi A Exp Hematol; 2006 Apr; 34(4):475-85. PubMed ID: 16569594 [TBL] [Abstract][Full Text] [Related]
14. Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells. Kloosterboer FM; van Luxemburg-Heijs SA; van Soest RA; Barbui AM; van Egmond HM; Strijbosch MP; Kester MG; Marijt WA; Goulmy E; Willemze R; Falkenburg JH Leukemia; 2004 Apr; 18(4):798-808. PubMed ID: 14973499 [TBL] [Abstract][Full Text] [Related]
15. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169 [TBL] [Abstract][Full Text] [Related]
16. A novel minor histocompatibility antigen recognized by HLA-A31 restricted cytotoxic T lymphocytes generated from HLA-identical bone marrow donor lymphocytes. Yazaki M; Takahashi T; Andho M; Akatsuka Y; Ito T; Miyake Y; Ito Y; Nakamura S; Wada Y Bone Marrow Transplant; 1999 Jul; 24(2):129-37. PubMed ID: 10455340 [TBL] [Abstract][Full Text] [Related]
17. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. de Rijke B; van Horssen-Zoetbrood A; Beekman JM; Otterud B; Maas F; Woestenenk R; Kester M; Leppert M; Schattenberg AV; de Witte T; van de Wiel-van Kemenade E; Dolstra H J Clin Invest; 2005 Dec; 115(12):3506-16. PubMed ID: 16322791 [TBL] [Abstract][Full Text] [Related]
18. Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes. Falkenburg JH; Goselink HM; van der Harst D; van Luxemburg-Heijs SA; Kooy-Winkelaar YM; Faber LM; de Kroon J; Brand A; Fibbe WE; Willemze R J Exp Med; 1991 Jul; 174(1):27-33. PubMed ID: 2056279 [TBL] [Abstract][Full Text] [Related]
19. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Choudhury A; Gajewski JL; Liang JC; Popat U; Claxton DF; Kliche KO; Andreeff M; Champlin RE Blood; 1997 Feb; 89(4):1133-42. PubMed ID: 9028934 [TBL] [Abstract][Full Text] [Related]
20. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Molldrem JJ; Clave E; Jiang YZ; Mavroudis D; Raptis A; Hensel N; Agarwala V; Barrett AJ Blood; 1997 Oct; 90(7):2529-34. PubMed ID: 9326217 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]